sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

NCT05332002 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Gastro-Intestinal Cancer

Interventions

DRUG: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)

Sponsor

Rutgers, The State University of New Jersey